Summary
VBIV Chart
Why Is VBI Vaccines (VBIV) Stock Up 62% Today?
VBI Vaccines (NASDAQ: VBIV ) stock is rising higher on Tuesday after the commercial-stage biopharmaceutical company filed for bankruptcy last week. According to a press release from VBI Vaccines, this bankruptcy filing is part of the company's ongoing restructuring effort.
VBI Vaccines Inc Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| NA Nizar Araji National Bank Of Canada /FI/ | 173.78 | $11.99 | $0.4 | -$11.59 | -96.66% |
VBI Vaccines Inc (VBIV) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
VBI Vaccines Inc Profile
| Biotechnology Industry | Healthcare Sector | Jeffery R. Baxter FCMA CEO | OTC PINK Exchange | 91822J103 CUSIP |
| US Country | 131 Employees | 28 Dec 2012 Last Dividend | 12 Apr 2023 Last Split | - IPO Date |
Overview
VBI Vaccines Inc. is a commercial-stage biopharmaceutical entity focused on the development and commercialization of vaccines for immuno-oncology and infectious diseases. Known for its innovative approach to vaccine development, the company has successfully brought to market multiple hepatitis B (HBV) vaccines, including PreHevbrio, PreHevbri, and Sci-B-Vac. Initially named SciVac Therapeutics Inc., the company underwent a rebranding to VBI Vaccines Inc. in May 2016 to better reflect its expanded focus and development portfolio. The company's strategic partnerships with entities such as Brii Biosciences Limited, the National Research Council of Canada, and the Coalition for Epidemic Preparedness Innovations highlight its collaborative approach to vaccine development and its commitment to addressing global health challenges. Headquartered in Cambridge, Massachusetts, VBI Vaccines Inc. positions itself as a key player in the biopharmaceutical industry with a broadening pipeline of therapeutic and prophylactic vaccine candidates.
Products and Services
- PreHevbrio, PreHevbri, and Sci-B-Vac – These are brand names under which the company's hepatitis B (HBV) vaccines are marketed. Each brand leverages unique formulations and approaches to provide immunity against HBV, a significant global health concern.
- VBI-2601 – A novel protein-based immunotherapeutic candidate that targets chronic HBV infections, aiming to improve patient outcomes by potentially offering a functional cure through immune system modulation.
- VBI-1901 – An experimental immunotherapeutic candidate for the treatment of glioblastoma, one of the most aggressive and lethal forms of brain cancer. VBI-1901 seeks to enhance patient's immune responses against cancer cells.
- VBI-1501 – A vaccine candidate designed as a preventive measure against cytomegalovirus (CMV) infections. By stimulating the immune system to defend against CMV, VBI-1501 could significantly reduce the incidence and impact of this widespread and potentially severe virus.
- VBI-2501 – Developed for the treatment of Zika virus, this vaccine candidate utilizes the company's innovative platform to provide protection against Zika, a virus known for causing severe birth defects during pregnancy and other health complications.
- Coronavirus Vaccine Candidates: VBI-2902, VBI-2901, and VBI-2905 – Representing VBI Vaccines Inc.'s response to the global COVID-19 pandemic, these candidates are in various stages of development and testing. Each candidate reflects the company's committed effort to leverage its technological and scientific expertise to combat coronavirus and its variants.
